Should I buy or sell Monopar Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares. View MNPR analyst ratings or view top-rated stocks .

What is Monopar Therapeutics' stock price target for 2024?

4 equities research analysts have issued twelve-month price objectives for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $24.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 4,167.9% from the stock's current price. View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts .

How have MNPR shares performed in 2023?

Monopar Therapeutics' stock was trading at $2.37 on January 1st, 2023. Since then, MNPR shares have decreased by 87.1% and is now trading at $0.3046. View the best growth stocks for 2023 here .

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 187,800 shares, an increase of 277.9% from the October 31st total of 49,700 shares. Based on an average trading volume of 923,400 shares, the short-interest ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are sold short. View Monopar Therapeutics' Short Interest .

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our MNPR earnings forecast .

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX) , Fulcrum Therapeutics (FULC) , Sorrento Therapeutics (SRNE) , Akero Therapeutics (AKRO) , Chimerix (CMRX) , Trevena (TRVN) , Aldeyra Therapeutics (ALDX) , Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST) .

When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Who are Monopar Therapeutics' major shareholders?

Monopar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Windsor Advisory Group LLC (0.64%). Insiders that own company stock include Andrew Cittadine and Tactic Pharma Llc. View institutional ownership trends .

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Monopar Therapeutics have any subsidiaries?

The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. Read More

Monopar Therapeutics Stock Price, News & Analysis (NASDAQ:MNPR)

$0.30

+0.01 (+3.39%)

(As of 11/29/2023 ET)

Compare

Today's Range: $0.29
▼
$0.33
50-Day Range: $0.29
▼
$0.60
52-Week Range: $0.27
▼
$3.82

Volume: 155,473 shs
Average Volume: 2.96 million shs
Market Capitalization: $4.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Monopar Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 4,167.9% Upside
$13.00 Price Target
Short Interest: Healthy
3.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.67) to ($0.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, Monopar Therapeutics has a forecasted upside of 4,167.9% from its current price of $0.30.
Amount of Analyst Coverage
Monopar Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.14% of the float of Monopar Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monopar Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Monopar Therapeutics has recently increased by 277.87%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Monopar Therapeutics does not currently pay a dividend.
Dividend Growth
Monopar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNPR.

2.5

News and Social Media Coverage

News Sentiment
Monopar Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for MNPR on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.18% of the stock of Monopar Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($0.67) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monopar Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monopar Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monopar Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MNPR Stock News Headlines

November 9, 2023 | finance.yahoo.com

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

November 9, 2023 | finance.yahoo.com

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | finance.yahoo.com

Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs

November 3, 2023 | markets.businessinsider.com

Promising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics Inc

November 1, 2023 | finance.yahoo.com

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

October 10, 2023 | finance.yahoo.com

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

September 5, 2023 | finance.yahoo.com

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 5, 2023 | finance.yahoo.com

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 10, 2023 | finance.yahoo.com

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

August 8, 2023 | finance.yahoo.com

Monopar Provides Encouraging Camsirubicin Clinical Data Update

August 8, 2023 | finance.yahoo.com

Monopar Provides Encouraging Camsirubicin Clinical Data Update

July 11, 2023 | finance.yahoo.com

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

July 11, 2023 | finance.yahoo.com

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

June 21, 2023 | finance.yahoo.com

Monopar to Participate in the Radiopharma Forum by the Lake 2023

June 14, 2023 | finance.yahoo.com

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

June 1, 2023 | msn.com

HC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy Recommendation

June 1, 2023 | finance.yahoo.com

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

June 1, 2023 | finance.yahoo.com

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

May 29, 2023 | finance.yahoo.com

Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

May 15, 2023 | markets.businessinsider.com

Expert Ratings for Monopar Therapeutics

May 15, 2023 | msn.com

HC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

Monopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright

May 13, 2023 | investing.com

Monopar Therapeutics (MNPR) Earnings Dates & Reports

May 11, 2023 | marketwatch.com

10-Q: MONOPAR THERAPEUTICS

May 11, 2023 | finance.yahoo.com

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

See More Headlines

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNPR
CUSIP: N/A
CIK: 1645469
Web: www.monopartx.com
Phone: 847-388-0349
Fax: N/A
Employees: 11
Year Founded: 2014

Price Target and Rating

Average Stock Price Target: $13.00
High Stock Price Target: $24.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +4,167.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -113.36%
Return on Assets: -86.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.32
Quick Ratio: 4.32

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.44 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 14,870,000
Free Float: 8,682,000
Market Cap: $4.53 million
Optionable: Not Optionable
Beta: 0.95

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Chandler D. Robinson M.B.A. (Age 39)
M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director
Comp: $708.12k
Ms. Kim R. Tsuchimoto CPA (Age 60)
CFO, Secretary, Treasurer & Director
Comp: $350.55k
Mr. Andrew J. Cittadine M.B.A. (Age 51)
Chief Operating Officer
Comp: $390.41k
Dr. Patrice P. Rioux M.D. (Age 72)
Ph.D., Acting Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Windsor Advisory Group LLC
Bought 89,974 shares on 10/31/2023
Ownership: 0.635%

View All Institutional Transactions

MNPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares.
View MNPR analyst ratings or view top-rated stocks.
What is Monopar Therapeutics' stock price target for 2024?: 4 equities research analysts have issued twelve-month price objectives for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $24.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 4,167.9% from the stock's current price.
View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts.
How have MNPR shares performed in 2023?: Monopar Therapeutics' stock was trading at $2.37 on January 1st, 2023. Since then, MNPR shares have decreased by 87.1% and is now trading at $0.3046.
View the best growth stocks for 2023 here.
Are investors shorting Monopar Therapeutics?: Monopar Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 187,800 shares, an increase of 277.9% from the October 31st total of 49,700 shares. Based on an average trading volume of 923,400 shares, the short-interest ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are sold short.
View Monopar Therapeutics' Short Interest.
When is Monopar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our MNPR earnings forecast.
How were Monopar Therapeutics' earnings last quarter?: Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).
When did Monopar Therapeutics IPO?: (MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.
Who are Monopar Therapeutics' major shareholders?: Monopar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Windsor Advisory Group LLC (0.64%). Insiders that own company stock include Andrew Cittadine and Tactic Pharma Llc.
View institutional ownership trends.
How do I buy shares of Monopar Therapeutics?: Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Monopar Therapeutics have any subsidiaries?: The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More

This page (NASDAQ:MNPR) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Monopar Therapeutics Stock Price, News & Analysis (NASDAQ:MNPR)

Monopar Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Monopar Therapeutics Stock (NASDAQ:MNPR)

MNPR Stock Price History

MNPR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

MNPR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™